X

Trial Profile

A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Q-1802 in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 31 Jul 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Q-1802 (Primary)
Indications Adenocarcinoma; Carcinoma; Gastric cancer; Gastrointestinal cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors QureBio

Most Recent Events

24 Jul 2023 Planned End Date changed from 1 Jan 2023 to 1 Jul 2024.
24 Jul 2023 Planned primary completion date changed from 1 Aug 2022 to 1 Apr 2024.
21 Jan 2023 Interim results (n=29, as of 20 Sep 2022) studying Q-1802 safety in relapsed/refractory advanced solid tumours were presented at the 2023 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com